# Monte Rosa Therapeutics, Inc. (GLUE) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Monte Rosa Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/GLUE/mda/fy2025/): filed 2026-03-17; accession 0001193125-26-109360 (https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/GLUE/mda/fy2024/): filed 2025-03-20; accession 0000950170-25-042344 (https://www.sec.gov/Archives/edgar/data/1826457/000095017025042344/glue-20241231.htm)
- [FY 2023 MD&A](/company/GLUE/mda/fy2023/): filed 2024-03-14; accession 0000950170-24-031150 (https://www.sec.gov/Archives/edgar/data/1826457/000095017024031150/glue-20231231.htm)
- [FY 2022 MD&A](/company/GLUE/mda/fy2022/): filed 2023-03-16; accession 0000950170-23-008440 (https://www.sec.gov/Archives/edgar/data/1826457/000095017023008440/glue-20221231.htm)
- [FY 2021 MD&A](/company/GLUE/mda/fy2021/): filed 2022-03-29; accession 0000950170-22-004927 (https://www.sec.gov/Archives/edgar/data/1826457/000095017022004927/glue-20211231.htm)

Back to /company/GLUE/